Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Operating Expenses (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Operating Expenses readings, the most recent being $17.8 million for Q1 2026.

  • Quarterly Operating Expenses rose 40.74% to $17.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $54.9 million through Mar 2026, down 4.7% year-over-year, with the annual reading at $49.7 million for FY2025, 20.43% down from the prior year.
  • Operating Expenses hit $17.8 million in Q1 2026 for Ovid Therapeutics, up from $13.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $20.7 million in Q2 2024 and bottomed at $10.8 million in Q4 2024.
  • Average Operating Expenses over 5 years is $14.5 million, with a median of $13.4 million recorded in 2024.
  • The largest annual shift saw Operating Expenses tumbled 53.63% in 2022 before it soared 50.01% in 2023.
  • Ovid Therapeutics' Operating Expenses stood at $12.2 million in 2022, then soared by 50.01% to $18.3 million in 2023, then crashed by 41.09% to $10.8 million in 2024, then grew by 20.49% to $13.0 million in 2025, then skyrocketed by 37.16% to $17.8 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Operating Expenses are $17.8 million (Q1 2026), $13.0 million (Q4 2025), and $12.7 million (Q3 2025).